1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Multivariate logistic regression analysis: odds of complications according to platelet-testing status
Complication OR^{^a} 95% CI P Value
Primary outcome: neurologic morbidity and neurologic mortality 2.37 0.95 to 5.93 .06
Secondary outcomes 
    Spontaneous rupture 1.46 0.28 to 7.67 .65
    Intracranial hemorrhage 6.56 0.50 to 85.80 .15
    Ischemic stroke 2.03 0.67 to 6.20 .21
    Parent artery stenosis 0.06 <0.001 to 24.51 .37
    Cranial neuropathy 1.17 0.22 to 6.38 .85
    Neurologic mortality 3.24 0.80 to 15.01 .13
    Neurologic morbidity 3.25 1.10 to 9.61 .03
    All-cause mortality 3.67 0.81 to 16.74 .09
↵a Shown are the odds in the platelet testing/PED group versus those in the PED alone group. For each of the complications, the OR is for the platelet testing/PED versus the PED alone group. The analysis was adjusted for age, gender, aneurysm size, number of aneurysms treated, use of multiple PEDs, practitioner's previous experience, and center volume.